Xiao Ping Ye
Chairman bij HANGZHOU TIGERMED CONSULTING CO., LTD
Vermogen: 1 110 M $ op 29-02-2024
Profiel
Momenteel is Xiao Ping Ye Voorzitter & General Manager bij Hangzhou Tigermed Consulting Co., Ltd. Dr. Ye zit ook in de raad van bestuur van Dian Diagnostics Group Co. Ltd., Coland Holdings Ltd., Shanghai Guochuang Pharmaceutical Co., Ltd. en HBM Holdings Ltd. Dr. Ye was voorheen Chief Medical Officer van Roche (China) Co. Ltd. Hij behaalde een doctoraat aan de Universiteit van Oxford.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
30-06-2023 | 132 929 656 ( 74.09% ) | 833 M $ | 29-02-2024 | |
01-02-2024 | 44 309 885 ( 7.78% ) | 278 M $ | 29-02-2024 |
Actieve functies van Xiao Ping Ye
Bedrijven | Functie | Begin |
---|---|---|
COLAND HOLDINGS LIMITED | Director/Board Member | 05-12-2010 |
HANGZHOU TIGERMED CONSULTING CO., LTD | Chairman | - |
HBM HOLDINGS LIMITED | Director/Board Member | 01-12-2020 |
Eerdere bekende functies van Xiao Ping Ye
Bedrijven | Functie | Einde |
---|---|---|
DIAN DIAGNOSTICS GROUP CO.,LTD. | Director/Board Member | 01-12-2022 |
Shanghai Guo Chuang Pharmaceutical Co., Ltd.
Shanghai Guo Chuang Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Guo Chuang Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of pharmaceutical products. Its products include pharmaceuticals against nervous system diseases, digestive system diseases, cardiovascular diseases, mental diseases, and immune system diseases. The company was founded on March 20, 2003 and is headquartered in Shanghai, China. | Director/Board Member | 01-10-2021 |
Shanghai LIDE Biotech Co. Ltd.
Shanghai LIDE Biotech Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai LIDE Biotech Co. Ltd. is a translational medicine service provider that specializes in oncology translational research and immuno oncology. The private company is based in Shanghai, China. The Chinese company has a growing bank of over 50 cell line-derived xenograft (cdx) mouse models that are used for preclinical drug efficacy testing. The benefits of cdx models are their cost effectiveness, fast turnaround time, and high efficiency of xenotransplantation. LIDE's FGI (Functional Genomic Imaging) platform leverages its K-cell technology and bioinformatics team to deliver next-generation transcription analysis. The primary benefit of CR (Conditionally Reprogrammed) cells is their intratumor and intertumor heterogeneity, even after amplification. | Director/Board Member | - |
Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd Medical/Nursing ServicesHealth Services Tigermed Consulting Co., Ltd. is a Contract Research Organization (CRO) in China that provides regulatory service, Phase I-IV clinical trials, data management & biostatistics, medical translations and GCP training services for healthcare products. The company was founded in 2002 and is headquartered in Shanghai, CN. | Director/Board Member | - |
Roche (China) Co. Ltd. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Xiao Ping Ye
University of Oxford | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
DIAN DIAGNOSTICS GROUP CO.,LTD. | Health Services |
HANGZHOU TIGERMED CONSULTING CO., LTD | Commercial Services |
HBM HOLDINGS LIMITED | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd Medical/Nursing ServicesHealth Services Tigermed Consulting Co., Ltd. is a Contract Research Organization (CRO) in China that provides regulatory service, Phase I-IV clinical trials, data management & biostatistics, medical translations and GCP training services for healthcare products. The company was founded in 2002 and is headquartered in Shanghai, CN. | Health Services |
Roche (China) Co. Ltd. | |
Coland Holdings Ltd.
Coland Holdings Ltd. Pharmaceuticals: MajorHealth Technology Coland Holdings Ltd. engages in the research, development, and sale of generic and traditional Chinese medicine, biochemical drugs, and medical equipment. It focuses on the treatment of hepatobiliary, respiratory system, tumor, and cardiovascular problems. The company was founded on March 23, 2010 and is headquartered in Shanghai, China. | Health Technology |
Shanghai Guo Chuang Pharmaceutical Co., Ltd.
Shanghai Guo Chuang Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Guo Chuang Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of pharmaceutical products. Its products include pharmaceuticals against nervous system diseases, digestive system diseases, cardiovascular diseases, mental diseases, and immune system diseases. The company was founded on March 20, 2003 and is headquartered in Shanghai, China. | Health Technology |
Shanghai LIDE Biotech Co. Ltd.
Shanghai LIDE Biotech Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai LIDE Biotech Co. Ltd. is a translational medicine service provider that specializes in oncology translational research and immuno oncology. The private company is based in Shanghai, China. The Chinese company has a growing bank of over 50 cell line-derived xenograft (cdx) mouse models that are used for preclinical drug efficacy testing. The benefits of cdx models are their cost effectiveness, fast turnaround time, and high efficiency of xenotransplantation. LIDE's FGI (Functional Genomic Imaging) platform leverages its K-cell technology and bioinformatics team to deliver next-generation transcription analysis. The primary benefit of CR (Conditionally Reprogrammed) cells is their intratumor and intertumor heterogeneity, even after amplification. | Commercial Services |